U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H15F3N4O5
Molecular Weight 436.3414
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TBA-354

SMILES

[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC3=CC=C(N=C3)C4=CC=C(OC(F)(F)F)C=C4

InChI

InChIKey=ZXSGSFMORAILEY-HNNXBMFYSA-N
InChI=1S/C19H15F3N4O5/c20-19(21,22)31-14-4-2-13(3-5-14)16-6-1-12(7-23-16)10-29-15-8-25-9-17(26(27)28)24-18(25)30-11-15/h1-7,9,15H,8,10-11H2/t15-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H15F3N4O5
Molecular Weight 436.3414
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.tballiance.org/news/tb-alliance-advances-next-generation-tb-drug-candidate-clinical-testing

TBA-354, also known as SN31354, is a potent anti-tuberculosis drug candidate. TBA-354 is narrow spectrum and bactericidal in vitro against replicating and nonreplicating Mycobacterium tuberculosis, with potency similar to that of delamanid and greater than that of PA-824. TBA-354 maintains activity against Mycobacterium tuberculosis H37Rv isogenic monoresistant strains and clinical drug-sensitive and drug-resistant isolates. TBA-354 is a promising next-generation nitroimidazole antitubercular agent. TBA-354 emerged from studies designed to identify a next generation nitroimidazole for TB. TB Alliance conducted the studies in collaboration with the University of Auckland and University of Illinois-Chicago. Once identified, TB Alliance further advanced TBA-354 through pre-clinical development and is now the sponsor of the Phase 1 study.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2049 ng/mL
20 mg/kg single, intraperitoneal
dose: 20 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
TBA-354 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
10135 ng × h/mL
20 mg/kg single, intraperitoneal
dose: 20 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
TBA-354 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.24 h
20 mg/kg single, intraperitoneal
dose: 20 mg/kg
route of administration: Intraperitoneal
experiment type: SINGLE
co-administered:
TBA-354 plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
3.5%
unknown, unknown
TBA-354 plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis.
2015 Jan
Patents

Sample Use Guides

10-1000 mg TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
Route of Administration: Oral
The MIC range for TBA-354 across the 10 M. tuberculosis strains tested was <0.02 to 0.36 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:36:35 GMT 2023
Edited
by admin
on Sat Dec 16 11:36:35 GMT 2023
Record UNII
911T37M2WY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TBA-354
Common Name English
TBA 354
Code English
(SN31354((S)-2-NITRO-6-((6-(4-TRIFLUOROMETHOXY)PHENYL)PYRIDINE-3-YL)METHOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE))
Systematic Name English
((6S)-6-((6-(4-(TRIFLUOROMETHOXY)PHENYL)-3-PYRIDYL)METHOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZIN-2-YL)AZINIC ACID
Systematic Name English
Code System Code Type Description
PUBCHEM
49836057
Created by admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
PRIMARY
CAS
1403987-02-9
Created by admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
NO STRUCTURE GIVEN
FDA UNII
911T37M2WY
Created by admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
PRIMARY
CAS
1257426-19-9
Created by admin on Sat Dec 16 11:36:35 GMT 2023 , Edited by admin on Sat Dec 16 11:36:35 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
MIC
Related Record Type Details
ACTIVE MOIETY
Official Title: A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects Purpose: The objective of the study is to evaluate the safety and tolerability of multiple doses of TBA-354 in healthy subjects.
ACTIVE MOIETY
TBA-354 MICs and MBCs against M. tuberculosis H37Rv: MIC (replicating) = 0.006 .MU.M, MBC (replicating) = 0.006 .MU.M, LORA (NR) MIC = 0.27 .MU.M, LORA (NR) MBC = 3.4 .MU.M, 4% BSAb MIC (replicating) = 0.011 .MU.M, 10% FBSc MIC (replicating) = 0.012 .MU.M
ACTIVE MOIETY
Originator: Global Alliance for TB Drug Development, University of Auckland; Developer: Global Alliance for TB Drug Development; Class: Antitubercular, Nitroimidazole, Oxazine, Pyridine, Small molecule; Mechanism of Action: Undefined mechanism; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Tuberculosis; Most Recent Events: 19 Nov 2015 Global Alliance for TB Drug Development plans a phase I trial in Healthy volunteers in USA (NCT02606214), 01 Jan 2015 Phase-I clinical trials in Tuberculosis (In volunteers) in USA (PO), 12 Sep 2012 Pharmacodynamics & pharmacokinetics data from preclinical studies in Tuberculosis presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)